The case for commercial leadership
Why Ambiki should revisit senior commercial leadership, and why I believe I can help build the system that turns a product advantage into a market advantage.
Ambiki appears to have a product advantage that its current commercial motion is not yet consistently converting into market advantage. The company does not primarily need more product surface or more demo capacity. It needs one accountable leader to connect positioning, demand generation, sales execution, onboarding, retention, and expansion into a measurable operating system.
Revisit the need for one accountable commercial leader, and evaluate me through a working process rather than deciding from a conventional interview alone.
Ambiki already has the assets a commercial leader would spend years creating: a differentiated vertical product, founder and practitioner credibility, strong sentiment, proprietary capabilities, a price advantage, and thousands of clinician resources. The missing layer is the system that converts them into qualified demand, won business, activation, retention, and expansion.
Ambiki’s product and price compared favorably with Fusion, but Fusion delivered the stronger buying experience.
A content footprint over 4,200 pages, yet only 5 genuinely non-branded top-20 rankings in a 134-keyword study.
Fifteen captured Meta ads amounted to one strategic message: no PMaaS angle, little economic-buyer proof.
Demo capacity appeared available; demand quality and conversion are the more likely constraints than calendar supply.
The same buyer-translation gap appears in advertising, website copy, the demo, pricing, and onboarding.
The decision requested from this week’s conversation
Agree to a structured working evaluation of the commercial mandate and my fit to lead it. The immediate next step does not need to be an offer or a reopened posting; it needs to be a real test of whether the work is necessary and whether we work well together.
My outside-in research produced five findings, none of them a product problem.
In a controlled secret shop, Ambiki demonstrated a better-fit product at roughly half the realistic cost of Fusion, yet Fusion delivered the much stronger commercial experience, scoring 4.1/5 against Ambiki’s 2.9/5. The largest gaps were positioning, value framing, competitive selling, and command of the next step, not software capability.
The site holds more than 4,200 URLs, roughly 2,800 of them clinician tools. Yet Ambiki ranked top-20 for only 5 genuinely non-branded terms in a 134-keyword study, with no top-three positions. Clinician affinity is built; a comparable commercial discovery engine is not.
The site and ads sell convenience to clinicians. The economic buyer purchases something larger: protected revenue, lower admin labor, better utilization, safer switching, fewer subscriptions, and operational support. The PMaaS model provides that story; it is fragmented or absent across ads, pages, demos, and quotes.
A 23-snapshot review of public demo availability found about 28% of reconstructed openings went unused. Ambiki does not first need more slots; it needs more qualified demand, a more disciplined sale, and a managed path from demo to activation to renewal.
This is not just a marketing problem, a rep-coaching problem, or a customer-success problem. The same buyer mismatch appears in acquisition, website copy, the demo, packaging, onboarding, and proof. Functional improvements help, but no isolated function can solve the whole system. That is the argument for a senior commercial owner.
The leverage sits across the buyer journey and in the handoffs, which is why the need cannot be reduced to “hire a marketer” or “coach the sales rep.”
Ambiki recently paused its search for a President and Chief Commercial Officer. I understand that decision. A senior commercial hire is consequential, and a previous hire who left after six months because of culture fit and insufficient command of the product and industry creates good reason to be deliberate.
This memo is not an argument for reflexively reopening the same search. It is an evidence-based case that the work behind the role still needs a clear owner, and that I may be unusually well suited to own it, because I have already invested in understanding Ambiki’s product, market, customer, funnel, and competitive environment before joining.
The original role combined four responsibilities:
A vertical SaaS company moving from founder-led growth toward a repeatable commercial system cannot optimize those responsibilities independently. Marketing can generate leads that sales does not convert. Sales can close accounts that onboarding cannot activate. Customer success can rescue accounts manually while the business remains unable to identify what predicts retention. Each function can look busy while the full system underperforms.
Who is accountable for turning Ambiki’s product advantage into a repeatable path from awareness to revenue to retention?
If the answer is distributed across the founders and several functional owners, the risk is not that no one works on it. The risk is that everyone improves a local part while no one owns the commercial result end to end.
I secret-shopped Ambiki and Fusion as the same prospective buyer: an eight-provider pediatric speech practice, commercial insurance plus self-pay, telehealth required, defined implementation window. The result was encouraging for Ambiki’s product and concerning for its motion.
| Dimension | Ambiki | Fusion | What it means |
|---|---|---|---|
| Overall buyer-experience score | 2.9 | 4.1 | The incumbent executed a more mature sale |
| Positioning & differentiation | 2 | 4 | Fusion named alternatives and framed risk; Ambiki didn’t assemble its advantages into a story |
| Pricing & value framing | 3 | 5 | Fusion produced a live quote; Ambiki deferred and never made the price advantage visible |
| Command of the process | 2 | 5 | Fusion set a mutual next step; Ambiki largely closed on starting a trial |
| Switch-risk mitigation | 4 | 4 | Ambiki’s onboarding and support model held up as a genuine strength |
Ambiki showed several practical advantages: an aging report, rapid autosave, no storage cap, Google Calendar sync, a generous onboarding-seat model, RCM assistance, and proprietary AI. Realistic monthly pricing was roughly $600 all-inversus Fusion’s quoted $1,186. But the rep never turned those facts into the simple commercial conclusion the buyer needed:
“For a pediatric practice like yours, Ambiki gives you the workflow depth and support you need at roughly half the cost, without the incumbent’s price creep and administrative constraints.”
Fusion did the opposite. It named Ambiki, characterized it as young and risky, used maturity as proof, quoted live, discovered the decision process, and scheduled a dated next step. Ambiki possessed the raw material for the better argument; Fusion made the better argument.
Secret shop: buyer-experience by axis (score out of 5)
The visible gap clusters around commercial execution (positioning, pricing, proof, and process) rather than switching support or basic product fit. Product gaps require engineering and capital; commercial gaps require disciplined leadership, enablement, and measurement. Ambiki’s problem is the more fixable one.
→ Full teardown with the tape: Secret-Shop & GTM Analysis
The role description emphasized Practice Management as a Service and a four-pillar thesis. Yet PMaaS did not appear in the secret-shopped conversation, and it has not been consistently prominent in the storefront. This leaves Ambiki marketed as another feature-rich platform when it has a more differentiated claim available: pediatric-therapy-native software; hands-on practice and billing support; proprietary workflow and clinical tools; consolidation of point solutions into one operating platform.
The product inventory strengthens the claim. Reconsil™, Tenalog®, Pacing™, Click Beacon™, Seamless Swap™, and Session Chaining™ are not generic feature-checklist language. They translate into fewer reconciliation errors, recovered clinician time, higher utilization, lower cost to serve teletherapy, and more usable clinical capacity. The site often stops one level early (“save time,” “everything in one place”) when the owner needs to hear: protect collections and reduce denials; return clinician hours to billable care; increase utilization without headcount; remove redundant software expense; reduce migration risk; gain a partner who helps the practice run.
→ Value-Copy Gap Analysis · Proprietary-Features Battlecard · Positioning by Discipline
A crawl found 4,222 URLs, roughly two-thirds supporting clinician tools and affinity (about 2,800 pages). That is a differentiated content moat, not wasted effort. But it mostly reaches practitioners searching for clinical help rather than owners choosing or replacing an EMR. The 134-keyword study made the mismatch measurable.
Ambiki top-20 search visibility by buyer-intent group
The shape is the problem: Ambiki is visible when the buyer already knows its name, then visibility collapses as search moves toward discovery. Counts are 10/10, 5/21, 4/65, and 1/38, and the five competitor-alternative rankings are Ambiki’s own “Ambiki vs. X” pages, not generic “X alternative” discovery terms. Meanwhile TheraPlatform appeared on 52% of the keyword set, SPRY on 36%, SimplePractice on 31%.
→ Acquisition Channels & SEO · Competitor Landscape
The June 29 archive captured 15 active Meta ads. Eleven images and four videos, but strategically one message repeated: “Stop juggling separate tools for scheduling, notes, billing, and teletherapy.” Credible, but it disproportionately attracts the solo or micro-practice whose pain is tool fragmentation. The higher-value insurance-billing practice buys on revenue integrity, administrative leverage, support, compliance, staff utilization, and switching risk. Neither PMaaS nor the strongest proprietary moat appeared in the captured set; every ad used the same “Learn more” direction and the same landing page. The opportunity is not “make more ads”; it is to run a commercial learning agenda optimized against qualified opportunity and eventual revenue, not clicks.
Across 23 public-calendar snapshots covering nine dates, the analysis reconstructed roughly 67 independent 45-minute openings. Nineteen appeared to remain unbooked (about 28%) and six of nine dates showed unused capacity. Directional, not an internal audit, but enough to reject the idea that growth is capped by an inability to take more demos. The likelier constraints: insufficient qualified demand, prospects reaching the wrong conversion path, inconsistent discovery, no standard mutual action plan, weak proof against incumbent risk narratives, and an unmeasured handoff from trial or sale into activation.
→ Demo Calendar Availability Analysis
Each finding can be assigned to a function, but the advantage comes from connecting them.
| Observed issue | Local fix | Integrated commercial requirement |
|---|---|---|
| Absent from buyer-intent searches | Publish SEO content | Tie traffic to ICP, opportunity quality, CAC, and revenue |
| Ads repeat one broad message | Test more creative | Segment assisted vs. self-serve motions; optimize to retained revenue |
| Demo shows features without a decisive story | Train the rep | Align positioning, discovery, competitive proof, pricing, next-step discipline |
| Trial substitutes for a sales process | Change the CTA | Define where trial belongs in each motion and what activation means |
| PMaaS is not fully articulated | Rewrite copy | Carry one value story from acquisition through renewal |
| High-touch onboarding appears valuable | Add documentation | Prove which onboarding milestones predict first renewal and expansion |
| Excellent rating, low review volume | Ask for reviews | Trigger asks from activated, healthy accounts; use proof in the sale |
| Pricing and packaging can be ambiguous | Make a price sheet | One source of truth across marketing, sales, CS, and automated recaps |
This is why I would be cautious about solving the problem by hiring only a demand-generation leader or only a sales leader. Either could improve a portion of the funnel while amplifying a downstream leak. The senior commercial leader should own a common set of outcomes: qualified pipeline, not lead volume; new-logo ARR, not demo count; win rate and cycle integrity, not activity; activation and time to first value, not merely go-live; gross and net revenue retention by cohort; expansion ARR and attach; CAC and payback by path; forecast accuracy and operating cadence.
That ownership does not require a large executive layer. It requires a hands-on operator with enough authority to align the functions and enough humility to work inside the details.
Eleven years in therapy and behavioral-health practice-management SaaS, including work at Therapy Brands across TheraNest and My Clients Plus. I understand the operating anxieties beneath an EMR decision: billing and collections, payer rules, documentation burden, compliance, staff adoption, migration risk, support responsiveness, and the fear of disrupting care while changing systems. My experience is deeper in behavioral health than in pediatric SLP/OT/PT, and I would not pretend otherwise, but I am not learning the economics of a therapy practice from scratch. The work in this folder is evidence of that extension: I studied product capabilities, proprietary tools, discipline depth, onboarding, pricing, sales calls, advertising, search visibility, review dynamics, competitors, and demo operations.
My career progressed from customer support to head of marketing to general manager. I have owned a P&L across a multi-product portfolio and led sales, marketing, and customer success as one operating system, with sales leadership reporting into me. That path matters because this role is not a conventional VP of Sales position; it requires someone who understands how an acquisition promise affects onboarding, how onboarding affects retention, how support becomes positioning, and how expansion changes the economics of acquisition. I have run growth through net revenue retention rather than treating new-logo sales as the finish line.
At Therapy Brands I worked around a multi-product portfolio including TheraNest and My Clients Plus, firsthand exposure to practice-management buyers, multi-product positioning, portfolio complexity, customer migrations, and the strengths and weaknesses of scaled incumbents. At TrustSpot I again worked across acquisition, customer value, retention, and expansion, helping produce 115%+ NRR. The category was different, but the operating lesson transfers: durable growth comes from aligning the promise made before the sale with the value realized after it.
Before receiving internal data or authority, I have produced a commercial-motion memo built around falsifiable hypotheses; a KPI tree and three-year forecast framework; a controlled secret-shop comparison; a 10-axis sales-call scorecard; an acquisition-channel and SEO analysis across 134 keywords; a competitor landscape and discipline map; a captured and analyzed 15-ad Meta library; a landing-page conversion analysis; a full product-feature inventory and proprietary-feature battlecard; a value-copy gap analysis; an SLP/OT/PT positioning analysis; a uniqueness statement for the economic buyer; an onboarding analysis; and a 23-snapshot demo-calendar study. The most credible response to concerns about industry knowledge and platform depth is not reassurance; it is proof of work.
Two secret-shopped calls are not a statistically representative sample. Public calendar availability is not internal capacity data. Search rankings change. The financial model uses illustrative assumptions until internal data replaces them. The consolidation-savings range needs validation against actual prospect stacks. I do not yet know Ambiki’s internal ARR, margins, conversion rates, cohort retention, team dynamics, support burden, or founder expectations well enough to prescribe a final org design. That is not a weakness in the proposal; it is the operating posture I would bring: separate what we know from what we infer, replace outside assumptions with internal data, and change course quickly where the evidence disagrees.
The prior outcome should influence both how Ambiki hires and how a candidate earns trust.
The founders should define the operating behaviors the role requires before redefining the title or profile. Questions I would want us to answer candidly:
I have begun that work and would propose making it an explicit part of the evaluation:
This would test product command, customer empathy, commercial judgment, working style, and culture fit more effectively than another sequence of conventional interviews.
The first 90 days should validate the mandate before expanding headcount or spend.
→ The measurement system in full: KPI & Forecast Model
Ambiki does not have to choose between immediately recreating the original executive role and doing nothing.
Revisit the full role with clarified decision rights, cultural expectations, six-month outcomes, and a working-session-based evaluation. Cleanest if the founders agree the need is enduring and want one owner for the full commercial lifecycle.
A defined engagement with access to the team, calls, systems, and data. The mandate: validate the diagnosis, install the commercial fundamentals, and produce a jointly agreed recommendation for the permanent structure. Lowers risk for both sides while testing what a normal interview cannot.
If “President & CCO” feels too broad for the stage, define a Head of Commercial or GM mandate with explicit ownership of marketing, sales, onboarding/CS alignment, funnel measurement, and retained revenue. The title matters less than the decision rights and outcome accountability.
The structure I would avoid is dividing the work into disconnected projects with no single owner. Ambiki’s opportunity is in the seams, and the seams are exactly what functional fragmentation leaves unattended.
I am not asking the founders to reverse a thoughtful hiring decision based on enthusiasm or volume of research. I am asking for a more specific reconsideration:
Ambiki has already built much of the hard part: a differentiated product, real therapy-practice credibility, proprietary capabilities, strong customer sentiment, a valuable clinician-content footprint, and a meaningful price advantage. What it has not yet fully built is the commercial machine that makes those advantages repeatable and visible to the right buyer.
The opportunity is not to manufacture demand around an undifferentiated product. It is to help a differentiated product become easier to discover, easier to buy, safer to adopt, and more valuable to retain.
That is work I know, in a market I understand, for a product I have already made a serious effort to learn.
The outside evidence justifies a working evaluation; internal proof could turn the thesis into an investment case.
Current ARR, new-logo ARR, ACV by practice size, win rate, sales cycle, pipeline coverage, forecast accuracy, quantifying the gap to the original sub-$1M-to-$10M+ mandate.
Visitor-to-trial, trial-to-demo, demo-to-opportunity, opportunity-to-win, activated-to-paid, and time to first value, split into self-serve and assisted journeys.
GRR, NRR, churn reasons, expansion, and support cost by segment and activation cohort, showing whether PMaaS is a retention moat, an onboarding necessity, or both.
Two or three named stories with before-and-after outcomes: hours saved, clean-claim rate, days in A/R, software retired, implementation time, or utilization.
A simple scenario showing the ARR impact of modest improvements in qualified pipeline, win rate, activation, and retention, the missing bridge from “there are gaps” to “the leadership investment pays for itself.”
I would not invent those numbers from public data. I would build this final layer with the founders from Ambiki’s actual metrics, an exercise that would itself be a useful test of how I work.